Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 28, 2012; 18(28): 3752-3760
Published online Jul 28, 2012. doi: 10.3748/wjg.v18.i28.3752
Figure 4
Figure 4 Safety evaluation. A: Xenoreactive antibodies levels during bioartificial liver treatments; B: Representative results of reverse transcription-polymerase chain reaction electrophoresis with the RNA extracted from the plasma. The ladder ranged from 100 bp to 600 bp. NBAL: Hybrid bioartificial liver; BAL: Bioartificial liver; PERV: Porcine endogenous retrovirus.